• 1
    Marsh JC, Gordon-Smith EC. CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy 2001;3: 189195.
  • 2
    Perotta A, Sunneberg TA, Scott J, et al. Rituximab in the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Blood 1999;94: 14a (abstract).
  • 3
    Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders prospects for anti-B cell therapy. Arthritis Rheum 2003;48: 14841492.
  • 4
    Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001;114: 891898.
  • 5
    Zaja F, De Vita S, Vianelli N, Ferraccioli G, Baccarani M, Fanin R. The new therapeutic indications for rituximab. Haematologica 2002; 88 (Suppl. 10): 2022.
  • 6
    Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002;69: 95100.
  • 7
    Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101: 38573861.
  • 8
    Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63: 803843.
  • 9
    Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs 2003;63: 12291243.
  • 10
    Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma 2004;45: 205219.
  • 11
    Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000;27: 7985.
  • 12
    British Committee for Standards in Haematology General Haematology Task Force.Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120: 574596.
  • 13
    Yang R, Han ZC. Pathogenesis and management of chronic idiopathic thrombocytopenic purpura: an update. Int J Hematol 2000;71: 1824.
  • 14
    Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic thrombocytopenic purpura. Blood 2001;98: 952957.
  • 15
    Aggarwal A, Catlett JP. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura. South Med J 2002;95: 12091212.
  • 16
    Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenia purpura. Blood 2002;99: 38723873.
  • 17
    Faurschou M, Hasselbalch HC, Nielsen OJ. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. Eur J Haematol 2001;66: 408411.
  • 18
    Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenic. Semin Oncol 2000;27(Suppl. 12):99103 .
  • 19
    Zaja F, Vianelli N, Sperotto A, et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003;88: 538546.
  • 20
    Patel K, Berman J, Ferber A, Caro J. Refractory autoimmune thrombocytopenic purpura treatment with rituximab. Am J Hematol 2001;67: 5960.
  • 21
    Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol 1993;84: 542544.
  • 22
    Cooper N, Bussel J. Rituximab treatment in patients with immune thrombocytopenia purpura (ITP). Blood 2001;98: 2180a (abstract).
  • 23
    Giagounidis AAN, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 antibody rituximab. Blood 2001;98: 2187a (abstract).
  • 24
    Introna M, Golay J, Barbui T. Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura. Haematologica 2003;88: 482484.
  • 25
    Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002;100: 22602262.
  • 26
    Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft versus host disease. Ann Intern Med 2000;133: 275279.
  • 27
    Hensel M, Ho AD. Successful treatment of a patient with hairy cell leukemia and pentostatin induced autoimmune thrombocytopenia with rituximab. Am J Haematol 2003;73: 3740.
  • 28
    Thomas AT. Autoimmune hemolytic anemias. In: WintrobeS, LeeGR, FoersterJ, LukensJ, ParaskevasF, GreerJP, RodgersGM, eds. Clinical Haematology, 10th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 1998: 12331263.
  • 29
    Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358: 15111513.
  • 30
    Lee E, Zamkoff KW, Gentile TC, Zimrin A. Rituxam in the treatment of autoimmune haemolytic anemia (AIHA). Blood 2000;96: 2560 (abstract).
  • 31
    Reddy S, Schwartz JM, Hussain S, Fernandez G. Rituximab-based therapy in 3 patients with autoimmune hemolytic anemia. Blood 2002;98: 3610 (abstract).
  • 32
    Ahrens N, Kingreen D, Seltsam A, Salama A. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Hematol 2001;114: 244245.
  • 33
    Gupta N, Kuvaru S, Patel D, et al. Rituximab based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16: 20922095.
  • 34
    Seipelt G, Bohme A, Koschmieder S, Hoelzer D. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. Ann Hematol 2001;80: 170173.
  • 35
    Chemnitz J, Draube A, Diehl V, Wolf J. Successful treatment of steroid and cyclophosphamide-resistant chronic lymphocytic leukemia with rituximab. Am J Hematol 2002;69: 232233.
  • 36
    Trape G, Fianchi L, Lai M, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 2003;88: 223225.
  • 37
    Iannitto E, Ammatuna E, Marino C, Cirrincione S, Greco G, Mariani G. Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody. Blood 2002;99: 10961097.
  • 38
    Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J 2002;4: 10061008.
  • 39
    Wong S, McKendrick J. Rituximab in lymphoma with life threatening haemolysis. Leuk Lymphoma 2002;43: 17111712.
  • 40
    Corti P, Bonanomi S, Vallinoto C, et al. Rituximab for immune hemolytic anemia following T and B-cell depleted hematopoietic stem cell transplantation. Acta Haematol 2003;109: 4345.
  • 41
    Ship A, May W, Lucas K. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell depleted haploidentical stem cell transplantation. Bone Marrow Trans 2002;29: 365366.
  • 42
    Hongeng S, Tardtong P, Worapongpaiboon S, Ungkanont A, Jootar S. Successful treatment of refractory autoimmune haemolytic anaemia in a post unrelated bone marrow transplant pediatric patient with rituximab. Bone Marrow Trans 2002;29: 871872.
  • 43
    Perotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002;116: 465467.
  • 44
    Mc Mahon C, Babu L, Hodgson A, Hayat A, Connell NO, Smith OP. Childhood refractory autoimmune haemolytic anaemia: is there a role for anti-CD20 therapy (rituximab). Br J Haematol 2002;117: 480483.
  • 45
    Berentsen S, Tjonnfjord GE, Brudevold R, et al. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001;115: 7983.
  • 46
    Zaja F, Russo D, Fuga G, et al. Rituximab in a case of cold agglutinin disease. Br J Haematol 2001;115: 230233.
  • 47
    Lavios N, Van Den Neste E, Jost E, Deneys V, Scheiff JM, Ferrant A. Remission of severe cold agglutinin disease after rituximab therapy. Leukemia 2001;15: 187188.
  • 48
    Cohen Y, Polliack A, Zelig O, Goldfarb A. Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma. Leuk Lymphoma 2001;42: 14051408.
  • 49
    Mori A, Tamaru J, Sumi H, Kondo H. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy. Eur J Haematol 2002;68: 243246.
  • 50
    Bauduer F. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20 positive, low-grade non Hodgkin's lymphoma. Br J Haematol 2001;112: 10851086.
  • 51
    Lee EJ, Kueck B. Rituximab in the treatment of cold agglutinin disease. Blood 1998;92: 34903491.
  • 52
    Morselli M, Luppi M, Potenza L, et al. Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment. Blood 2002;99: 34783479.
  • 53
    Camou F, Viallard IF, Pellegrin JL. Rituximab in cold agglutinin disease. Rev Med Interne 2003;24: 501504.
  • 54
    Engelhardt M, Jakob A, Ruter B, Trepel M, Hirsch F, Lubbert M. Severe cold hemaglutinin disease (CHD) successfully treated with rituximab. Blood 2002;100: 19221923.
  • 55
    Sparling TG, Andricevic M, Wass H. Remission of cold hemagglutinin disease induced by rituximab therapy. CMAJ 2001;164: 1405.
  • 56
    Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999;84: 11571158.
  • 57
    Auner HW, Wolfler A, Beham-Schmid C, Strunk D, Linkesch W, Sill H. Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment. Br J Haematol 2002;116: 727728.
  • 58
    Zecca M, DeStefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe immuno-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001;97: 39953997.
  • 59
    Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002;99: 10921094.
  • 60
    Batlle M, Ribera JM, Oriol A, Plensa E, Milla F, Felin E. Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukemia. Br J Haematol 2002;118: 11921193.
  • 61
    Maschan AA, Skorobogatova EV, Balashow DN, et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major AB incompatible peripheral blood allogenic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transpl 2002;30: 405407.
  • 62
    Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000;96: 11841186.
  • 63
    Rodon P, Breton P, Courouble G. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukemia with Campath-1H. Eur J Haematol 2003;70: 319321.